Abstract: An aircraft with an engine support structure, the aircraft including at least an engine wherein the at least engine is top mounted to an aircraft, a main body, and an engine support structure including a plurality of hoop structures, wherein at least one horseshoe structure is located forward of the center of gravity to the at least engine.

Abstract: A syringe assembly includes a syringe barrel (12) having a proximal end and a distal end, a needle hub (20) supporting the needle and coupled to the distal end of the syringe barrel (12). A moveable shield (36) is included for sliding from a first position where the needle is exposed a first length, a second position where the needle is exposed a second length less than said first length, and a third position covering a distal end of the needle. A locking mechanism (48, 86) is included to retain the shield in the second position while enabling the shield to slide to the third position, and to lock the shield in the third position to prevent re-use of the syringe.

Abstract: An aircraft with an engine support structure, the aircraft including at least an engine wherein the at least engine is top mounted to an aircraft, a main body, and an engine support structure including a plurality of hoop structures, wherein at least one horseshoe structure is located forward of the center of gravity to the at least engine.

Abstract: A tanker aircraft for long-distance travel, the tanker aircraft including a blended wing body having a main body, a transition, and wings with no clear demarcation between the wings and the main body along a leading edge of the tanker aircraft, a fuel storage located within the blended wing body, the fuel storage comprising a first fuel store, the first fuel store located within the transition and configured for long range flight and a second fuel store the second fuel store having a tanker capacity and a refueling boom system having a flying boom, the flying boom extending from the blended wing body, wherein the tanker aircraft is a long-range tanker aircraft.

Abstract: A commercial aircraft for short distance air travel, the commercial aircraft comprising a blended wing body aircraft having a main body, a transition and wings with no clear demarcation between the wings and the main body along a leading edge of the commercial aircraft, a passenger cabin, the passenger cabin located within the main body and having a wide body passenger capacity, at least a propulsor, the at least a propulsor attached to a portion of the main body and configured to propel the blended wing body commercial aircraft through air, a fuel storage located within the blended wing body, the fuel storage having a fuel capacity wherein the fuel capacity is configured for a fuel capacity associated with short-range flight, and a landing gear, the landing gear located on an undercarriage of the blended wing body, the landing gear configured for the short-range flight.

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

Abstract: A negative pressure wound therapy apparatus can include a housing, a negative pressure source supported by the housing and configured to aspirate fluid from a wound covered by a wound dressing, a switch positioned on an exterior surface of the housing, and a controller configured to operate the negative pressure source. The controller can be configured to, responsive to receiving a first user input via the switch, operate the negative pressure source to aspirate fluid from the wound at a first fluid flow rate. The controller can be configured to, responsive to receiving a second user input via the switch subsequent to receiving the first user input, operate the negative pressure source to aspirate fluid from the wound at a second fluid flow rate greater than the first fluid flow rate.

Abstract: A negative pressure wound therapy device can be configured to monitor motion and determine that the device is falling as well as duration and height of the fall. Flat falls and rotating falls can be accurately detected. The device can provide an indication of the fall, including deactivating therapy. The device can monitor the amount exudate removed from a wound and determine whether transition to a low-exudate rate negative pressure wound therapy and suggest such transition. The device can utilize proportional-inte-gral-derivative (PID) control loop to drive a negative pressure source of the device. The PID control loop can utilize different proportional gain and integral gain for different negative pressure setpoint to achieve target pressure quickly and without any large overshoots.

Abstract: A device for stimulating vitamin D production in a tissue. The device comprises a UV-B light source configured to emit light with a wavelength between 280 nm and 320 nm; and at least one tissue penetrating member optically coupled to the UV-B light source to deliver light emitted from the UV-B light source into the tissue, wherein the at least one tissue penetrating member has a length greater than or equal to 10 ?m and less than 10 mm.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.

Abstract: The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

Abstract: Aspects of the disclosure are directed to methods and compositions for treating or preventing an allergic airway disease in a subject in need thereof. Certain aspects relate to treatment with an effective amount of a composition comprising one or more Dickkopf-1 (Dkk-1) inhibitors and/or one or more additional allergic airway disease therapies. Further aspects relate to methods of reducing airway inflammation, reducing airway hyper-responsiveness, and/or inhibiting an adaptive or innate immune response in the airway of a subject comprising administering to the subject an effective amount of a composition comprising one or more Dkk-1 inhibitors and/or one or more additional allergic airway disease therapies.

Abstract: The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

Abstract: The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

Abstract: The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

Abstract: A method is described herein, comprising vaporizing a glycol material by thermal contact with a heating medium to form a vaporized glycol stream, increasing a pressure of the vaporized glycol stream to form a pressurized glycol stream, and increasing a temperature of the heating medium by thermally contacting the heating medium with the pressurized glycol stream.